ATE540698T1 - Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen - Google Patents

Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen

Info

Publication number
ATE540698T1
ATE540698T1 AT06774644T AT06774644T ATE540698T1 AT E540698 T1 ATE540698 T1 AT E540698T1 AT 06774644 T AT06774644 T AT 06774644T AT 06774644 T AT06774644 T AT 06774644T AT E540698 T1 ATE540698 T1 AT E540698T1
Authority
AT
Austria
Prior art keywords
virus
camptothecines
fluoropyrimidines
viruses
cancer treatment
Prior art date
Application number
AT06774644T
Other languages
English (en)
Inventor
Robert Lorence
Michael Roberts
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of ATE540698T1 publication Critical patent/ATE540698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06774644T 2005-07-14 2006-07-12 Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen ATE540698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69919505P 2005-07-14 2005-07-14
PCT/US2006/027018 WO2007011601A2 (en) 2005-07-14 2006-07-12 Cancer treatment using viruses, fluoropyrimidines and camptothecins

Publications (1)

Publication Number Publication Date
ATE540698T1 true ATE540698T1 (de) 2012-01-15

Family

ID=37669342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06774644T ATE540698T1 (de) 2005-07-14 2006-07-12 Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen

Country Status (14)

Country Link
US (2) US7767200B2 (de)
EP (1) EP1907015B1 (de)
JP (1) JP5190958B2 (de)
KR (1) KR20080039344A (de)
CN (1) CN101400368B (de)
AT (1) ATE540698T1 (de)
AU (1) AU2006270297B2 (de)
CA (1) CA2612949C (de)
IL (1) IL186730A0 (de)
MX (1) MX2007015407A (de)
NZ (1) NZ562951A (de)
RU (1) RU2435586C2 (de)
WO (1) WO2007011601A2 (de)
ZA (1) ZA200708840B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
US7900230B2 (en) * 2005-04-01 2011-03-01 The Directv Group, Inc. Intelligent two-way switching network
US8019275B2 (en) 2005-10-12 2011-09-13 The Directv Group, Inc. Band upconverter approach to KA/KU signal distribution
US7991348B2 (en) 2005-10-12 2011-08-02 The Directv Group, Inc. Triple band combining approach to satellite signal distribution
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
RU2496873C1 (ru) * 2012-06-04 2013-10-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (НГУ) ШТАММ ЭНТЕРОВИРУСА КОКСАКИ В6, СЕЛЕКТИВНО ИНФИЦИРУЮЩИЙ И ЛИЗИРУЮЩИЙ ОПУХОЛЕВЫЕ КЛЕТКИ ЧЕЛОВЕКА in vitro
CN112773812A (zh) * 2020-12-30 2021-05-11 烟台大学 新型喜树碱衍生物制备抗肿瘤药物的应用
CN112704683A (zh) * 2020-12-30 2021-04-27 烟台大学 一种新型喜树碱衍生物及其制备抗肿瘤药物的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
WO1994025627A1 (en) * 1993-04-30 1994-11-10 Lorence Robert M Methods of treating and detecting cancer using viruses
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
CA2234060A1 (en) 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
CZ133898A3 (cs) 1995-11-02 1998-08-12 Glaxo Wellcome Inc. Způsob výroby derivátů camptothecinu
GB9600438D0 (en) 1996-01-10 1996-03-13 Pharmacia Spa Hexacyclic camptothecin analogues, and process for preparing them
GB9601779D0 (en) 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
GB9702807D0 (en) 1997-02-12 1997-04-02 Pharmacia & Upjohn Spa Alkynyl-substituted camptothecins and process for their preparation
GB9715821D0 (en) 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives
GB9721070D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
KR20010072228A (ko) 1998-08-05 2001-07-31 추후제출 위장 독성이 감소된 캠프토테신 유도체의 용도
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
HUP0302278A3 (en) * 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
WO2001057204A1 (fr) 2000-02-02 2001-08-09 Yasufumi Kaneda Vecteur d'enveloppe virale pour transfert de gene
CA2397240A1 (en) 2000-02-29 2001-09-07 Peter Albert Palmer Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001070275A2 (en) 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
GB0008928D0 (en) 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
CA2409932A1 (en) 2000-06-01 2001-12-06 Sloan-Kettering Institute For Cancer Research Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US7348003B2 (en) * 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20040253272A1 (en) 2001-08-02 2004-12-16 Yasufumi Kaneda Process for producing inactivated virus envelopes
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
WO2005113013A2 (en) 2004-05-20 2005-12-01 Theravir Management L.P. Compositions of ndv and methods of use thereof for treatment of cancer
IL145397A0 (en) 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
TW200306314A (en) 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
US6593334B1 (en) 2002-05-02 2003-07-15 The University Of North Carolina At Chapel Hill Camptothecin-taxoid conjugates as antimitotic and antitumor agents
ITRM20020306A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
AU2003243380A1 (en) 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
US20040034050A1 (en) 2002-06-03 2004-02-19 Yang Li-Xi Homo-camptothecin derivatives
US20050220818A1 (en) 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
US6759416B2 (en) 2002-08-06 2004-07-06 Panorama Research, Inc. Anticancer conjugates of camptothecin and unsaturated fatty acids
JP4746877B2 (ja) 2002-11-01 2011-08-10 ジェノミディア株式会社 不活性化されたセンダイウイルスエンベロープを有効成分とする抗癌剤
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US20060018884A1 (en) 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
CA2566156A1 (en) 2004-05-28 2005-12-08 Pfizer Products Inc. Method for treating abnormal cell growth

Also Published As

Publication number Publication date
JP2009501230A (ja) 2009-01-15
JP5190958B2 (ja) 2013-04-24
AU2006270297A1 (en) 2007-01-25
CN101400368B (zh) 2012-10-03
IL186730A0 (en) 2008-02-09
RU2008105603A (ru) 2009-08-20
EP1907015A4 (de) 2009-03-18
EP1907015B1 (de) 2012-01-11
WO2007011601A2 (en) 2007-01-25
CA2612949C (en) 2015-04-28
NZ562951A (en) 2011-09-30
WO2007011601A3 (en) 2007-11-08
AU2006270297B2 (en) 2013-01-17
ZA200708840B (en) 2008-08-27
US20080193419A1 (en) 2008-08-14
CA2612949A1 (en) 2007-01-25
CN101400368A (zh) 2009-04-01
US20110117060A1 (en) 2011-05-19
RU2435586C2 (ru) 2011-12-10
MX2007015407A (es) 2008-02-19
US7767200B2 (en) 2010-08-03
EP1907015A2 (de) 2008-04-09
KR20080039344A (ko) 2008-05-07

Similar Documents

Publication Publication Date Title
ATE540698T1 (de) Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
PH12015500355A1 (en) Compounds for the treatment of paramoxyvirus viral infections
PH12017501534A1 (en) Antiviral compounds
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
MX2021002168A (es) Compuestos antivirales.
EA201690978A1 (ru) ПИРРОЛО[1.2-f][1.2.4]ТРИАЗИНЫ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫХ ВИРУСНЫХ ИНФЕКЦИЙ
EA201301158A1 (ru) Противовирусные соединения
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
EA200901241A1 (ru) Соединения для лечения гепатита с
EA200701850A1 (ru) Соединения трициклических нуклеозидов (варианты), фармацевтическая композиция на их основе и способ лечения или профилактики вирусных инфекций у млекопитающих
BRPI0511834A (pt) métodos por tratar hepatite c
BRPI0511078A (pt) compostos de pirimidinona cìclicos, composição compreendendo os mesmos, método de inibição e uso
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
EA200602289A1 (ru) Применение иматиниба для лечения нарушений работы печени и вирусных инфекций
EA201290993A1 (ru) Нуклеозидфосфорамидаты
CY1113038T1 (el) Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου
BRPI0612124A2 (pt) derivados de heteroarila para o tratamento de viroses
EA200971096A1 (ru) Терапевтические композиции и их применение
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
TW200719898A (en) 6-membered aryl and heteroaryl derivatives for treating viruses
HK1096583A1 (en) Cancer treatment using viruses and camptothecins
DK1479691T3 (da) Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c